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Melanoma is one of the aggressive cancer types. Mutations
that lock the BRAF protein in an active state may cause excessive
signaling in the pathway, leading to uncontrolled cell growth and
survival. Primarily among the BRAF mutations observed in mela-
noma, over 90% are supposed to be at codon 600, resulting in sub-
stitution of glutamic acid for valine, V600E (T > A transversion)
located in exon 15, BRAFV600E. Of particular interest is BRAF neg-
ative melanoma. This type of melanoma is not sensitive to BRAF
inhibitors and approaches to therapy require further study. We
aimed to investigate the frequency of BRAF V600 mutations in 80
patients with primary melanoma and determine the relationship
between mutations and clinical/pathologic features. Genomic
DNA was extracted from biopsy specimens with prevalent per-
centage of tumor cells by DNA-sorb B isolation kit (Amplisense,
Russia). BRAF V600E mutation was estimated by real-time PCR-
based assay for the BRAF V600E mutation allele-specific DNA test
(BioLink, Russia). Breslow thickness was assessed by applying
commercial Infinity Capture, Infinity Analyze Software. The
lymphocytic infiltration was determined in all tumors and
classified as ‘‘brisk”, ‘‘nonbrisk”, and ‘‘absent” according to criteria
established by Clark et al. Tumor infiltrating lymphocytes (TIL)
were identified as lymphocytes within tumor nodes. ‘‘Brisk”
infiltrate was determined in case of a diffuse presence of lympho-
cytes within tumor, ‘‘non-brisk” infiltrate was in focal location of
lymphocytes and ‘‘absent” if no lymphocytes were present in a
tumor. Mitotic activitywas determined asmitotic count on 10 high
power fields. For all patients, clinical and pathologic features
were tested for significant association with BRAF V600E mutation
status using simple cross tabulations, Fisher’s exact test, Pearson’s
v2 test, and/or non-parametric Mann–Whitney U test. The P
values lower 0.05 were considered as significant. BRAF V600E
mutation was detected in 41.25% of tested tumours. Patients with
BRAF-mutant and non-BRAF mutant melanoma were matched by
age and gender. Superficial spreading melanomawas observed in
66.2% of patients with wild-type BRAF, nodular melanoma in
21.2%, both lentigo-melanoma and acral-lentiginous melanomain
6.3% and mucosal melanoma in 1 3.0% of patients. In wild-type
BRAF melanoma patients, 59.7% tumors had ‘‘brisk” infiltrate,
14.8% – ‘‘non-brisk”, and 12 25.5% had no infiltrate. There was
no found correlation between BRAF status and tumor localization,
clinico-pathological type of tumor, TIL status, Breslow thickness
and mitotic rate. However, when cases were stratified by age, it
was revealed that melanoma patients aged above 80 years
were preferentially BRAF-negative (p < 0.05). BRAF-negative
melanomas occurred significantly more frequent in superficial
spreading type of the tumor. The localization of melanomas was
different between the patients with mutant BRAF status and
patients with wild-type BRAF status with regard to elderly and
younger patients (p = 0.03). The mean age was 54.4 years for
patients with BRAF-mutant melanoma localized on the trunk
and 63.7 years for patients with wild-type BRAF. In our study, no
relationship between BRAF status and tumor localization was
found, although tumors localized on extremities had tendency
to be BRAF V600E negative. Although our study revealed no any
other associations between melanoma prognostic markers and
BRAF V600E status, melanoma mutational profiling identification
may be important for predicting a worse prognosis in certain
patients.
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During cancer development, tumor cells gain the ability to
invade and metastasize. Individual cells use alternative migration
modes based on different cellular mechanisms. One of them is
mesenchymal motility mode which is driven by leading edge
protrusion in the form of filopodia or/and lamellipodia based on
Arp2/3 dependent actin polymerization. Mesenchymal motility
depends on formation of cell-substrate adhesions, activity of
matrix metalloproteases (MMPs) and on activity of small
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